RBC Capital Mkts initiated coverage on Design Therapeutics with a new price target
$DSGN
Biotechnology: Pharmaceutical Preparations
Health Care
RBC Capital Mkts initiated coverage of Design Therapeutics with a rating of Outperform and set a new price target of $30.00